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ABSTRACT
Vincamine is a poorly soluble potent neuroprotector and cerebral vasodilator, used for the treatment of CNS disorders. In some cases the bioavailability of pure compounds is strongly influenced by the co-administration of other constituents and in some cases the so called “phytocomplex” may act as enhancer of absorption of selected phytochemicals. In this paper, the oral bioavailability of vincamine when administered as a standardized Vinca minor L. leaf dry extract rather than pure indole alkaloid is demonstrated to be higher. 
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INTRODUCTION
Despite the large use of herbal medicine and nutraceuticals containing plant extract few investigations have until now considered the differences between the bioavailability of the active compound when administered as an extract and the pure chemical entities.
The well-established, successful use of some herbal extracts as health promoting products or complementary treatments for different diseases makes it critical to find a rationale for their pharmacological and therapeutic superiority over isolated single constituents. Several mechanisms of synergic effects have been proposed, mainly based on pharmacokinetic or physicochemical effects and improved solubility and enhanced bioavailability. For example, it is well known that some polyphenols or saponins increase the solubility and/or the absorption rate of major constituents in the extract thereby enhance their bioavailability by some kind of pharmacokinetic effect, resulting in a greater effectiveness of the extract than the isolated constituents’ thereof. In particular, the flavonol-triglycosides in the leaf extract of Atropa belladonna act as “absorption catalyzer” that enhance effectiveness of the product [1]. Khellin, the main active of the Ammi visnaga extract is rapidly and completely absorbed when administered as the extract, pure equimolar Khellin, is not fully absorbed until 60 min [2]. A similar example of the bioavailability enhancement is that of Hypericin in the Hypericum perforatum extract. In fact, the plasma level of hypericin is clearly higher, and a strong antidepressant effect is obtained, when it is combined with the polyphenols epicatechin, procyanidin, hyperosid or rutin, which are normally present in the extract. Conversely, hypericin alone only possesses a weak antidepressant effect, due to its extremely poor bioavailability [3].
In this perspective, in the present research the oral bioavailability of a Vinca minor Linne  leaf dry extract (Vinca Minor L.) was compared to that of its main active component, vincamine, in order to study the possibility of enhancing the poor oral bioavailability of this indole alkaloid and, at the same time, of explaining the differences in their oral absorption rates and extents. 
Vinca minor L. is indigenous to many parts of Europe growing in woods and thickets and is completely different from Vinca rosea (Madagascar-the proper name is Catharantus roseus) which contains the anticancer active ingredients vincristine and vinblastine [4]. Its main alkaloid, Vincamine is a recognized neuroprotector and cerebral vasodilator, well tolerated in human, with few side effects if administered at appropriate dose [5]. However, due to scarce wettability and low solubility in intestinal fluid, this compound suffers from relatively low oral bioavailability (20%) [6]. 
In the first step, we standardized a leaf extract enriched in vincamine in order to ensure the requested therapeutic dose with a suitable amount of dry extract. In fact, it is well known that the amount of Lesser Periwinkle’s alkaloid and particularly that of vincamine varies to a large extent as a function of the climatic conditions, season of herb gathering and its location [7].
Then, a comparison between physico-chemical characterisation of standard and dry extract vincamine was conducted to highlight possible differences in the solid-state of the drug and to recognize the existence of physical or chemical interactions with the other components of the dry extract. The research encompassed in vitro dissolution tests of Vinca minor L. dry extract and pure drug in simulated intestinal fluid. Finally, the in vivo studies were carried out in rats followed by the pharmacokinetic analysis of the plasma profiles.
2. Materials and methods
2.1 Materials
Vincamine was a kind gift from Linnea SA (Riazzino-Locarno, CH). The Vinca minor L. leaf dry extract was obtained from Flarer S.A. (Lugano, CH). All other analytical-grade chemicals and solvents of HPLC grade were provided by Carlo Erba (Milan, Italy).
2.2 Methods
2.2.1. HPLC Analysis of vincamine content in the dry extract 
The vincamine content in the dry extract was determined by HPLC-MS. Twenty mg of dry extract (20 mg) was exactly weighed in a test tube and extracted with 10 mL of methanol in ultrasound bath at room temperature for 10 minutes. After centrifugation and liquid collection, the extraction was repeated 3 times. Liquids were collected in a 100 ml volumetric flask and diluted with acetonitrile. The liquid was filtered through a syringe filter (RC 0.45 µm, Phenomenex, Castel Maggiore, Bologna, Italy) to remove any particles, the solution was diluted 1:100 with acetonitrile and used for HPLC analysis. 
2.2.2. HPLC-MS analysis 
The HPLC system used was a Varian LC212 equipped with 430 autosampler and with a 500-MS mass detector. The chromatographic separation was performed at room temperature, using an Agilent C-8 (2.1 x 150 mm) column. The mobile phases were acetonitrile (Solvent A) and water with 0.1% formic acid (Solvent B). Solvents were delivered at a flow rate of 200 µL/min. Gradient elution was used starting from 90% B then in 5 min to 100% A. The total run time was 8 min. The mass spectrometer operated in the positive ion mode with a needle voltage of 5000 V, shield voltage 600 V, drying temperature 350°C, nebuliser gas pressure 25.0 psi and drying gas pressure 15.0 psi. The MS/MS approach was used for a selective detection of vincamine and the precursor ion at m/z 355 and parent ion at m/z 337 were selected in MS/MS mode. The Calibration curve for vincamine consisted in different standard solutions (prepared and analysed in triplicate) ranging from 2 to 640 ng/mL. The limit of quantification was 2 ng/mL and the precision and accuracy were under 3% for all calibration points. Furthermore, fingerprinting of extract was obtained working in full MS mode and using a different separation system. Namely an Agilent C-18 (2.1 x 150 mm) was used. Mobile phases were the same as before but gradient elution was starting from 90% B then in 89 min to 35% A. The total run time was 90 min and retention time of vincamine was 27.9 min. As reference compounds apovincamine (MW 336 Da) and vincamone (MW 294 Da) were also used. Chromatograms of the standard mixture and of the extract and alkaloid MS spectra are reported in supplementary material file. Furthermore, fingerprinting of phenolic constituents of the extract was also obtained by HPLC-MS in negative ion mode using the Agilent C-18 (2.1 x 150 mm) column as a stationary phase. Mobile phases were the same as before but gradient elution was starting from 90% B then in 45 minutes to 30% B then in 51 minutes 0% B. A chromatogram with the main recorded species is reported in the supplementary information file. The mass spectrometer operated in the negative ion mode with a needle voltage of 5300 V, shield voltage of 600 V, drying temperature 350°C, nebuliser gas pressure 25.0 psi, drying gas pressure 15.0 psi, to obtain MS/MS fragmentation the turbo data depending scanning mode (tdds) was used.
2.2.3. Powder X-ray Diffraction Studies (PXRD)
PXRD patterns were recorded using a D500 (Siemens, Munich, Germany) diffractometer with Cu-K radiation (1.5418 Å), monochromatised by a secondary flat graphite crystal. All the analyses were performed in duplicate using a current at 20 mA and the voltage was set at 40 kV. The powder samples were scanned in the range from 5 to 35° of 2 angle, steps were of 0.05° of 2, and the counting time was of 5 sec/step.
2.2.4. Differential scanning calorimetry (DSC)
Calorimetric analyses were carried out by means of a differential scanning calorimeter (Mod. TA 4000, equipped with a measuring cell DSC 20 Mettler) using the STARe software version 9.30. The calibration of the instrument was performed with indium, zinc and lead for the temperature, and with indium for the measurement of the enthalpy. Samples of pure vincamine or dry extract, containing about 2 mg of vincamine, were placed in pierced aluminum pans and heated at a scanning rate of 10°C per min from 30 to 270°C, under static air atmosphere. All the analyses were performed in triplicate.
2.2.5. Solid-state Nuclear Magnetic Resonance (SSNMR) spectroscopy 
SSNMR spectra were recorded on a Bruker Avance II 400 instrument operating at 400.23, 100.64 and 40.55 MHz for 1H, 13C and 15N nuclei, respectively. Cylindrical 4 mm o.d. zirconia rotors with a sample volume of 60 μL were employed and spun at 12 (13C) or 7 (15N) kHz. A ramp cross-polarisation pulse sequence was used with a contact time of 3-4 ms, a 1H 90° pulse of 2.9 μs, recycle delays of 8 s, and 1000 (13C) or 16000 (15N) transients. A two pulse phase modulation (TPPM) decoupling scheme was used with an rf field of 75 kHz. 13C and 15N chemical shift scales were referenced with the resonance of hexamethylbenzene (13C methyl signal at 17.4 ppm) and (NH4)2SO4 (15N signal at 355.8 ppm with respect to CH3NO2). 
2.2.6.  X-ray Photoelectron Spectroscopy (XPS)
All XPS spectra were acquired at room temperature in normal emission geometry using a conventional Mg Kα X-ray source (hν=1253.6 eV) and hemispherical electron energy analyzer (overall energy resolution: about 0.8 eV). The binding energy scale has been calibrated by fixing the C 1s photoemission line due to hydrocarbon to 284.6 eV. All spectra were normalized to the incident photon flux and were analysed by performing a non-linear mean square fit of the data following the Levenberg-Marquardt algorithm, by using Igor 6 software. A linear background was used and the total photoemission intensity was reproduced by using Gaussian profiles.

2.2.7.  Dissolution kinetic tests (DKT) 
The dissolution medium was 150 cm3 of 0.2 M KH2PO4/0.2 M NaOH (pH 7.4) at 37°C, since vincamine solubility is pH-dependent and is particularly scarce in intestinal buffer. To use the in vitro dissolution as prediction of the in vivo performance of each product, sink conditions were not maintained during dissolution in order to build up the supersaturation, as commonly occurs under finite volume conditions in the gastro-intestinal tract and to allow possible events such as nucleation, crystallization and precipitation to proceed [8]. Accordingly, at time zero, a suitable amount of sample (pure drug or dry extract) to give 900 mg of active ingredient was added to the release environment. Each release test lasted 3 hours. Uniformity conditions were ensured by an impeller (stirring rate 200 rpm). The amount of vincamine solubilised at each time point was quantified by HPLC-MS analysis. Each formulation was tested in triplicate and the standard deviation (s.d.) did not exceed 5%. 
2.2.8. Solubility studies
Vincamine solubility at equilibrium (Cs) was determined by adding an excess of pure vincamine or dry extract to give 10 g of active in 150 cm3 of pH 7.4 buffer maintained at 37°C and stirred at 200 rpm. The adequate time for equilibration was reached after 26 h of testing. The amount of vincamine solubilised was quantified by HPLC-MS analysis. The experiment was performed in triplicate and the mean value ± s.d. was recorded.
2.2.9.  In vivo absorption studies
All the procedures for rats care and management performed in this research complied with those required by Italian laws (D.L.vo 116/92) and associated guidelines in the European Communities Council Directive of 24 November 1986 (86/609 ECC) and adhered to ethical standards for humane treatment of experimental animals established by the ethical committee of University of Trieste. 
Sprague-Dawley rats (400-450 g weight) were fasted, with free access to water, 12 hours before the experiment. The pure drug or the dry extract were administered as aqueous suspensions (2 ml corresponding to a dose 100 mg/kg of vincamine) by gastric gavage. Each experimental formulation was tested in 5 rats. The kinetic experiment lasted 24 hours. Blood samples (600 µl) were obtained using the “cannulated” tail artery method [9] already applied in our previous works [10, 11], allowing for several consecutive blood withdrawals in the same subject, with a very low level of stress in the animal. This method permits to reduce intra subject variability and hence it results in a reduction of the number of animals needed for the study. Blood collection was performed (using tubes containing 66 µl of a 40 mM tetrasodium EDTA solution) at 0.25, 0.5, 1, 2, 4, 6 and 24 hours after administration. After collection, the samples were centrifuged at 166 g for 10 min and plasma was separated and immediately frozen at -80°C, and stored at this temperature till the analysis.
2.2.10.  Assays of vincamine in plasma samples
For the determination of vincamine in plasma samples, 600 µL methanol were added to 200 µL plasma, and the resulting mixture was vortexed for 6 min. After centrifugation (1800 g for 13 min), 5 µL of the solution was injected. The vincamine determination in plasma samples was carried out using the previously described HPLC-MS method.
2.2.11. Pharmacokinetic analysis
Non-compartmental pharmacokinetic analysis was performed using WinNonlin Version 2.1 (Pharsight Corporation, Mountain View, CA) software. The area under the plasma concentration-time curve up to the last measured concentration at 24 h (AUClast) was calculated using the linear trapezoidal method. Time and value of maximum plasma concentration (tmax and Cmax, respectively) were reported as observed. Terminal half-life (t1/2) was calculated as t1/2 = ln2 / , where  is the terminal slope of the concentration profile on the semi-log plot calculated by linear regression. 





3. Results and Discussion

The use of dried standardised extract can be an attractive alternative to the administration of purified vincamine for treatment of memory disorders or as a CNS stimulant. The extract used is a brown-yellowish colored powder, with a typical herbal fragrance. It is a standardized hydroalcoholic dry extract of Vinca minor L.  containing the indole alkaloids vincamine (MW 355) and as minor constituents apovincamine (Mw 337), and traces of vincamone (295) and vincadifformine (MW 339) (Fig. 1). Furthermore, glycosyl-conjugated flavonoids (quercetin and kaempferol derivatives) were also detected (Chromatograms are reported as supplementary material). The amount of vincamine was determined by HPLC - MS analysis, and the dry extract contained 40.6% of the alkaloid vincamine (on dry weight). A detailed physico-chemical characterisation of vincamine in the dry extract was then performed, using the pure alkaloid as a comparison. 
Powder X-ray diffraction (PXRD) was employed to check solid-state of the drug in the dry extract. The patterns of the dry extract and pure vincamine are shown in Fig. 2. Alpha
Vincamine shows the typical pattern of a crystalline substance, exhibiting very intense and sharp signals, the mains of which fall at 2θ angles of 8.00°, 10.50 °, 12.10°, 12.60 °, 13.25 °, 13.95°, 16.7°, 17.50° and 23.10°.
In the pattern of the dry extract the main peaks of vincamine can be recognized despite minor shifts in location and peak splitting phenomena. This means that vincamine is present mainly as a crystalline solid in the dry extract and it represents the main crystalline fraction of the dry extract. As for the quantification of the vincamine crystalline fraction in the dry extract, this calculation was not possible. In fact, since the baseline of the two diffraction patterns (vincamine and dry extract) is only super-imposable in the interval 5°-12° 2θ, and an intense scattering phenomenon is visible after 12° 2θ in the dry extract pattern, only two peaks (8.00° and 10.50° 2θ) can be compared to ascertain the vincamine crystallinity in the dry extract. The intensity of these two reflections is compatible with a vincamine content of 40.6% in the extract.  
As previously mentioned the occurrence of splitting and broadening phenomena of vincamine peaks can be also noticed. These facts can be a sign of interactions among vincamine and other components of the extract. The diffuse background evident at angles greater than 12° of 2θ indicates the presence of amorphous components in the extract. 
As a further analysis, DSC was employed to examine once again a sample of pure vincamine and the dry extract. Their DSC curves are shown in Fig. 3. 
Pure vincamine exhibits an endothermal event at 240.9° C, due to its solid-liquid transition, which is accompanied by its exothermic degradation. The DSC curve of the dry extract first shows a broad endotherm with two shoulders, attributable to the loss of the moisture content (about 2.2%). This event is followed by the fusion of vincamine that occurs in this case at lower temperatures (melting peak at 227.2 °C) than the pure active substance, and it is followed also in this case by its degradation. The diminution and the broadening of the melting peak in agreement to previous PXRD pattern testifies the presence of interactions among vincamine and other components of the extract matrix. In the considered temperature range, with the only exception of a moderate "shoulder" at about 180 ° C, there are no other thermal events related to the presence of the other crystalline components of the extract.
Subsequently, the same two samples were analyzed using the SSNMR technique. Important factors that influence the chemical shift are charge density (electronic density and distribution), interactions among components, the chemical environment and the physical state [12]. In particular, the presence of amorphous solids usually causes a broadening of the peaks. 
Fig. 4 reports the 13C CPMAS spectra of pure vincamine and Vinca minor L. dry extract. Table 1 lists all chemical shifts of pure vincamine (reported from ref [13] together with the atom labeling we will refer to through the text) and extra resonances present in the Vinca minor L. dry extract spectrum.
Comparing the 13C spectrum of the dry extract and pure vincamine, a great similarity can be noticed, testifying that major signals are due to vincamine in agreement to its predominant presence in the extract with respect to any other sub-component. Other minor peaks are due to the great heterogeneity of compounds in the phytocomplex (see Table 1). Moreover, the lack of relevant resonance shifts of the vincamine in the extract with respect to those of pure vincamine suggests that it is mainly present in its original packing. Small variations in the shape of the peaks (a moderate broadening in the 13C spectrum of the dry extract) are ascribed to a certain degree of amorphous vincamine.
The 15N CPMAS spectra of the same samples (shown in Fig. 5) were also recorded. Indeed, it has been demonstrated that the 15N shift can be a reliable probe of the nitrogen protonation state as well as of hydrogen bond interactions present at nitrogen atoms [14]. Due to the low sensitivity of the 15N experiments, [15] the signals generated by the dry extract are almost exclusively associated with the vincamine, testifying that other indole alkaloids or other containing nitrogen molecules are present in the extract at negligible concentrations. Looking at these spectra an important difference between the two samples is immediately clear: the dry extract spectrum, apart from the vincamine signals at 12.0 (N4) and 117.2 (N1) ppm, shows a small additional peak not present in that of vincamine. This signal, lying at 21.8 ppm, is attribuited to protonated nitrogen in the vincamine of the extract (see later) [16]. Conversely, vincamine spectrum exhibits only a signal at 12.0 ppm assigned to the nitrogen 4 (N4). The presence of the signal at 21.8 ppm suggests that in the extract two types of vincamine can be recognized: a portion of vincamine is identical to the pure one, another portion contains the nitrogen (N4) in protonated form. This interaction site can be the reason of the differences previously observed also by  DSC and PXRD analyses. 
The presence of the unprotonated vincamine is also attested by the fact that the signals of C14 at 82.6 ppm (Fig. 4) and N4 at 12.0 ppm (Fig. 5) are found in the extract in the same position of the pure vincamine. These two atoms are involved in the hydrogen bond N···HO, that is a characteristic feature of the original packing of vincamine as previously reported [13].
The characterisation of the samples is pursued also through the use of XPS. This technique is highly representative for what concerns the characterisation of individual atoms’ chemical surroundings. It is reported to be ideally suited for establishing the location of the protons [17]. In this study this technique has been employed in order to support the assumption that, in the case of dry extract, a quote of vincamine contains the nitrogen in protonated form. Fig. 6 compares the XPS spectra of vincamine and dry extract. 
The N 1s spectrum of pure vincamine shows two components, corresponding to the two in-equivalent nitrogen atoms present in the molecule, N1 and N4 (Fig. 6a). The photoelectrons coming from N1 have higher binding energy than those of N4, due to aromaticity involving the unpaired doublet, as a consequence we attribute the component found at 400.1eV to N1, and that found at 399.0 eV to the N4.
In the vincamine present in the extract, (Fig. 6b) in addition to the previous ones, a further component is present at the highest binding energy (401.6 eV). Actually the positive charge of protonated nitrogen atoms is reflected in the N 1s core level with a shift at higher binding energy, so we can attribute the appearance of this component as the signature that protonation has occurred.  
Then, in vitro dissolution kinetics were studied, comparing the performance of the extract and the pure substance in simulated intestinal buffer during 3 hours of analysis. The following profiles were recorded (Fig. 7).
The pure alkaloid dissolved very slowly and a maximum concentration of about 12 mg/L was reached after 3 hours (Fig. 7a). In these conditions, the equilibrium solubility (42.3 ± 1.9 mg/L) was reached after 26 h. Conversely, the solubilisation of the indole alkaloid embedded in the dry extract was rapid and almost instantaneous, getting very high concentrations (ranging about 4000 mg/L) in only 10 minutes. After this concentration peak, the solubilised vincamine diminished very rapidly, reaching a plateau of solubilised amount for all the duration of the test. The Vincamine Cs released from the dry extract (844 ± 2.8 mg/L) is nearly 20 times that of pure vincamine. These results confirm the previous physico-chemical characterisation, supporting the presence of protonated vincamine probably due to the interaction with other components of the plant extract. Salification represents one of the most common approaches to enhance solubility/bioavailability of poorly soluble drugs. In fact,  the higher oral bioavailability of vincamine hydrochloride compared to its free base has been previously established [18]. These data also suggest the action of the other phytoconsituents, which helps the solubilisation process both in terms of rate and extent of solubilisation. It must be remembered that poorly soluble molecule such as quercetine or kaempferol in the extract are in the glycosyl-conjugated form and hence their water solubility is enhanced [19] and can favor the solubilisation of poorly soluble vincamine.
It must also be evidenced that, although in vitro results were excellent, the superiority of vincamine’s dissolution profile in the dry extract was attested onlt on the base of  the very low standard deviation values  and no statistical analysis was performed on these data.
Finally, oral bioavailability of vincamine formulated as an aqueous suspension of pure drug or dry extract was compared in two groups of rats (n=5 per group). Vincamine was administered at a dose of 100 mg/kg by gastric gavage. These investigations were carried out to check whether the in vitro superiority of the dry extract on the vincamine alone corresponded to an effectively superior in vivo performance. The resulting plasma concentration profiles are shown in Fig. 8, pharmacokinetic parameters are listed in Table 2. The superiority in the in vivo performance of the dry extract compared to pure vincamine was clearly demonstrated. Namely, as evidenced by AUClast which was almost 7-fold (6.9) higher and Cmax which was 2.3-fold higher, bioavailability of vincamine was significantly higher, when administered as dry extract, compared to pure vincamine. Therefore, the effect on bioavailability may be the underlying mechanism for the synergistic action of the total plant extract. 
Furthermore, although in both cases vincamine is promptly absorbed, resulting in a median tmax of 0.5 h and 0.75 h with administration of pure vincamine and dry extract, respectively, there is an additional difference which can be observed in the two plasma concentration profiles. It must be noticed that when the dry extract was administered, in addition to higher Cmax, terminal half-life (t1/2) was longer (Table 2). This may be the result of the so called flip-flop phenomenon, where the terminal half-life reflects prolonged slow absorption. Consequently, with administration of the dry extract, elevated plasma concentrations were maintained for 24h, assuring the possibility of a prolonged vincamine effect.  
This “phyto-kinetic” synergistic action is presumably mediated by the presence of many hydrophilic compounds, present in the extract. According to the physico-chemical characterisation and in vitro solubilisation kinetics, the interactions of vincamine with these compounds favor the solubilisation process and hence promote the vincamine absorption. In addition, there may be some unidentified components, which acting as surfactants may enhance the intestinal permeation of the drug and hence improve its bioavailability.  

4. Conclusions
This work presents the comparison of the pharmacokinetic performance of a standardised Vinca minor L. dry extract compared to the isolated vincamine, and can be considered as an example of advantageous administration of an extract compared to a purified product. As such, it may represent an effort towards a more “rational” phytotherapy. The physicochemical characterisation of the active in the extract is not a common practice and the investigation of the oral absorption of the two products with the help of a proper pharmacokinetic analysis is as well a rare example of supporting a more evidence-based support to determine objectively the efficacy of herbal drugs. 
From the experimental evidence of the results reported in this study, the presence in the dry extract  of crystalline vincamine partially in a salt form was pointed out. Moreover, the interaction of the un-protonated vincamine with the phytocomplex present in the dry extract contributed favorably to the in vitro dissolution and in vivo absorption. In fact, the V. minor leaf dry extract used in this study resulted in a seven-fold improvement in oral bioavailability compared to isolated active ingredient. As dry extracts from different manufacturers can show significant differences in active components’ content and in the absorption and bioavailability of putative active ingredients, these considerations are limited to the dry extract used in this research and bioavailability of other Vinca Minor L.  extracts should be characterized on a case by case basis.
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